Exenatide
Aliases: Byetta · Bydureon · Exendin-4 analog
Last verified: 2026-09-23
The short version
The first GLP-1 agonist (2005), modeled on exendin-4 from the Gila monster. Historically important; now largely superseded.
Identity & type
- Molecular type
- analog
- Origin
- The first GLP-1 agonist (2005), modeled on exendin-4 from the Gila monster.
Mechanism of action
DPP-4-resistant GLP-1R agonist.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. Byetta 5–10 mcg twice daily; Bydureon 2 mg weekly.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Byetta 5–10 mcg twice daily; Bydureon 2 mg weekly. The first GLP-1 drug: historically important, rare today; users described mild weight loss and nausea with twice-daily dosing.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
The first GLP-1 drug: historically important, rare today; users described mild weight loss and nausea with twice-daily dosing.
Protocol — official vs community
Official / label
Two formulations. Byetta: 5 mcg SC twice daily, within 60 minutes before morning and evening meals; Bydureon BCise: 2 mg SC once weekly. Adjunct to metformin/sulfonylurea etc. in type 2 diabetes.
- 01Weeks 1–4 (Byetta): 5 mcg twice daily
- 02Week 5+ (Byetta): increase to 10 mcg twice daily based on glycemic response/tolerability
Duration: Chronic while effective; EXSCEL confirmed CV safety without a superiority signal.
The first GLP-1 receptor agonist (2005). Twice-daily pre-meal timing and higher nausea rates are why newer weekly agents have largely replaced it.
Community (anecdotal)
Where still encountered, mirrors the label: Byetta 5–10 mcg twice daily before meals, or the 2 mg weekly pen.
- Cycle:
- Continuous.
- Break:
- None by design.
Community presence is now mostly historical or cost-driven; it is the GLP-1 class's proof-of-concept, not its current practice.
Human evidence
Pioneering GLP-1-class trials; EXSCEL CV safety.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Nausea (more than newer agents), hypoglycemia with sulfonylureas.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials